



# Who we are

## **Profile**

As a venture capital company, HBM BioVentures is invested globally in some 30 mature emerging companies in the biotechnology/human medicine, diagnostics and medical technology sectors. The lead products of many of HBM BioVentures' portfolio companies are either at an advanced stage of development or already available on the market. The Company focuses on unlisted emerging companies, with two-thirds of assets being invested in private companies that offer high value creation potential. This has enabled HBM BioVentures to carve out a unique and distinctive market position. HBM BioVentures has a broad shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

## **Portfolio Strategy**


HBM BioVentures has started sales negotiations for several portfolio companies and is participating actively in the selling processes. As demand from major pharma and biotech companies for new products continues to rise, and with many mature portfolio companies, HBM BioVentures is well positioned for successful divestments.

HBM BioVentures' investment activity is currently focused on follow-on financing for existing portfolio companies. Each individual financing round is analysed in detail from the scientific, technical, business, financial, legal and patent perspectives. Investments are made only in companies that have attractive value-creation potential. HBM BioVentures takes an active role and entrepreneurial responsibility in each of the 20 largest private portfolio companies.

# At a Glance


## Allocation of assets<sup>1)</sup>

Mainly invested in private companies with high value-creation potential.




## Currency allocation of net assets<sup>1)</sup>

Emphasis on US dollar investments.




## Development phase of portfolio companies<sup>2)</sup>

Primarily invested in profitable emerging companies or in emerging companies with products already available on the market.



## Therapeutic area of the lead products of portfolio companies<sup>2)</sup>

Broadly diversified areas of activity.



As at 30.6.2010:

<sup>1)</sup> Total assets: CHF 687 million

<sup>2)</sup> Investments: CHF 621 million

<sup>3)</sup> After sale of US dollar hedge position on 2 July 2010

# Key Figures

	30.6.2010	31.3.2010
<b>Net assets (CHF 000)</b>	<b>646,133</b>	<b>666,148</b>
Cash and cash equivalents	32,103	129,084
Disbursed	621,304	632,918
Investments in private companies	438,455	440,104
<b>Net asset value (NAV) per share (CHF)</b>	<b>65.00</b>	<b>65.85</b>
<b>Share price (CHF)</b>	<b>40.00</b>	<b>49.50</b>
<b>Performance of net assets</b>		
In the quarter 1.4. – 30.6.2010	-1%	
Since start of business (12.7.2001)	-34%	
<b>Performance of relevant market indices (in CHF)</b>		
NBI – Nasdaq Biotech Index (since 12.7.2001)	-44%	
MSCI World Pharma Index (since 12.7.2001)	-50%	
<b>Number of shares issued (registered shares)</b>	<b>10,700,000</b>	<b>10,700,000</b>
Number of shares outstanding (registered shares)	9,939,805	10,115,599
<b>Number of registered shareholders</b>	<b>1,209</b>	<b>1,268</b>

<b>The 12 largest investments as at 30.6.2010<sup>1)</sup></b>		
	Fair value (CHF 000)	As % of net assets
<b>Private companies</b>		
PharmaSwiss	97,789	15.1
PTC Therapeutics	41,674	6.4
mtm laboratories	33,666	5.2
Cathay Industrial Biotech	30,167	4.7
Pacira Pharmaceutical	22,221	3.4
Lux Biosciences	18,452	2.9
ChemoCentryx	18,232	2.8
Interventional Spine	17,224	2.7
Ophthotech	16,609	2.6
Nereus Pharmaceuticals	14,686	2.3
<b>Public companies</b>		
Micrus Endovascular <sup>p)</sup>	33,314	5.2
Basilea Pharmaceutica <sup>p)</sup>	29,102	4.5

<sup>p)</sup> Position originating from the private companies portfolio.

<sup>1)</sup> Excluding specialised venture capital funds.

# Management Report

## Dear Shareholders

Three significant events dominated the first reporting quarter of the 2010/2011 financial year:

- > Mr Hans Peter Hasler was appointed new Chairman of the Board of HBM BioVentures Ltd on the date of the 2010 Ordinary Shareholders' Meeting. Mr Hasler has had a successful career at a number of major pharmaceuticals companies. Most recently, he was Chief Operating Officer at Biogen Idec, one of the world's largest biotechnology firms. Now that Dr Henri B. Meier and Prof. Ulrich Abshagen have stepped down, the Board of Directors comprises five members. Dr Meier will remain closely associated with the Company as its Honorary Chairman.
- > Astellas, the international pharmaceuticals company with its head office in Tokyo that recently acquired OSI Pharmaceuticals, confirmed that it will retain the 10.5% equity stake in HBM BioVentures, and will also seek to further step up its cooperation with HBM.
- > HBM BioVentures maintains appropriate levels of liquidity even after the full repayment of the convertible bond in April 2010. In early July, the Company sold the US dollar hedging position built up at the end of May. Following this liquidity injection of CHF 11.5 million, cash and cash equivalents now stand at more than CHF 40 million. HBM BioVentures could also raise over CHF 50 million more by selling investments in public companies.

HBM BioVentures closed the first three months (1 April to 30 June 2010) of the current 2010/2011 financial year with a loss of CHF 11.6 million. The net asset value (NAV) per share came to CHF 65.00 as at the end of June (-1.3%). There were no major changes to the valuations of our investment holdings. Among other factors, the quarter was nonetheless characterised by very high volatility on the foreign exchange markets.

### Private portfolio companies

A concerted effort is being made with regard to the sale of several private portfolio companies. Some of these processes are already under negotiation. HBM BioVentures also continued to support a number of existing portfolio companies with follow-on financings. These included PTC Therapeutics (USD 3.2 million as the second tranche of a total USD 6.4 million), Nabriva (EUR 1.4 million), Pacira (USD 3.75 million), Cylene (USD 1.1 million) and Lux Biosciences (USD 1.0 million). Valuation adjustments of USD – 6.1 million and USD – 1.2 million were made to the investment holdings in Surface Logix and Ansaris respectively.

### Investment portfolio

Just under 80% of HBM BioVentures' current investment portfolio is composed of positions in private companies, more than half of which (in terms of investment volume) are operating profitably or already selling products on the market. The numerous investment holdings in North America, combined with investments in Asian companies, mean that some 58% of the portfolio is held in US dollars (after the US dollar hedge was sold on 2 July 2010). Other investment holdings are mainly in euros (24%) and Swiss francs (15%). Foreign exchange risks are not hedged at present. Investments in public portfolio companies have been trimmed back a little further.

The Ordinary Shareholders' Meeting on 25 June 2010 approved the cancellation of an additional 500,000 shares. Given recent buy-backs, once these shares have been cancelled the number of outstanding shares will already have been reduced by approximately 10%.

During the quarter under review, the Board of Directors decided to apply a modified fee model as of 1 April 2011. This lends greater weight to HBM BioVentures' share price. From then on, 80% of the management fee will be calculated on the basis of the company's assets, and the remaining 20% on the basis of its market capitalisation. The fee has so far been calculated fully on the basis of the Company's assets. All other fee regulations remain unchanged.

## Outlook

Several of HBM BioVentures' portfolio companies are currently in negotiations on either a trade sale or a cooperation with a larger partner in the industry. We anticipate that some of these negotiations will conclude in successful deals over the coming six to nine months. These transactions should increase HBM BioVentures' net asset value and generate liquidity. The operating businesses of our more mature portfolio companies are developing well, and our research companies are also making good progress with their clinical trials. These advances underscore not only the value and stability of the investment portfolio, but also the future prospects of emerging companies that are still at the development stage.



Dr Andreas Wicki  
CEO



Dr Joachim Rudolf  
CFO

# Consolidated Quarterly Financial Statements

Consolidated balance sheet

(CHF 000)	Notes	30.6.2010	31.3.2010
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents		32,103	129,084
Financial instruments	(2)	10,162	0
Receivables		5,722	5,992
Inventories		530	539
<b>Total current assets</b>		<b>48,517</b>	<b>135,615</b>
<b>Non-current assets</b>			
Investments	(3)	621,304	632,918
Other financial assets		11,586	11,385
Property, plant and equipment		171	212
Intangible assets		5,825	5,825
<b>Total non-current assets</b>		<b>638,886</b>	<b>650,340</b>
<b>Total assets</b>		<b>687,403</b>	<b>785,955</b>
<b>Liabilities</b>			
<b>Short-term liabilities</b>			
Short-term financial liabilities	(4)	7,059	84,284
Other short-term liabilities		4,617	5,982
<b>Total short-term liabilities</b>		<b>11,676</b>	<b>90,266</b>
<b>Long-term liabilities</b>			
Long-term financial liabilities	(4)	29,594	29,541
<b>Total long-term liabilities</b>		<b>29,594</b>	<b>29,541</b>
<b>Shareholders' equity</b>			
Share capital	(5)	642,000	642,000
Treasury shares	(5)	-38,140	-30,358
Capital reserve		363,425	363,900
Currency translation differences		-285	-153
Accumulated loss		-320,867	-309,241
<b>Total shareholders' equity</b>		<b>646,133</b>	<b>666,148</b>
<b>Total liabilities and shareholders' equity</b>		<b>687,403</b>	<b>785,955</b>
Number of outstanding shares (in 000)		9,940	10,116
Net asset value (NAV) per share (CHF)		65.00	65.85



# Consolidated Quarterly Financial Statements

Consolidated statement of income for the period 1 April to 30 June

(CHF 000)	Notes	Quarter ended 30.6.2010	Quarter ended 30.6.2009
<b>Result from investment activity</b>			
Gains on investments	(3)	18,851	33,064
Losses on investments	(3)	-34,711	-32,929
Gains from currency hedging transactions	(2)	10,162	0
<b>Gross result from investment activity</b>		<b>-5,698</b>	<b>135</b>
<b>Result from product sales</b>			
Revenues from product sales		54	0
Costs of products sold		-67	0
<b>Gross result from product sales</b>		<b>-13</b>	<b>0</b>
<b>Gross result</b>		<b>-5,711</b>	<b>135</b>
Management fee	(7)	-2,900	-3,000
Personnel expenses		-893	-434
Other operating expenses		-904	-482
Depreciation and amortisation		-43	0
<b>Operating result before interest and taxes</b>		<b>-10,451</b>	<b>-3,781</b>
Financial income		13	1,564
Financial expenses		-1,188	-2,534
<b>Result before taxes</b>		<b>-11,626</b>	<b>-4,751</b>
Income taxes		0	0
<b>Net result for the period</b>		<b>-11,626</b>	<b>-4,751</b>
Number of outstanding shares, time-weighted (in 000)		10,027	10,526
Basic earnings per share (CHF)		-1.16	-0.45

As the Company does not have options or similar instruments outstanding, diluted earnings per share are identical to basic earnings per share.

## Consolidated statement of comprehensive income for the period 1 April to 30 June

<b>Net result for the period according to consolidated statement of income</b>	<b>-11,626</b>	<b>-4,751</b>
<b>Contribution to operating result reported in shareholders' equity</b>		
Change owing to currency translation differences	-132	0
<b>Total comprehensive result for the period</b>	<b>-11,758</b>	<b>-4,751</b>

# Consolidated Quarterly Financial Statements

Consolidated statement of cash flows for the period 1 April to 30 June

(CHF 000)	Quarter ended 30.6.2010	Quarter ended 30.6.2009
Revenues received from product sales	43	0
Paid costs of products sold	-51	0
Management fee paid	-2,900	-4,230
Other expenses paid (personnel and other operating expenses)	-2,009	-1,436
<b>Net cash flow from operating activities</b>	<b>-4,917</b>	<b>-5,666</b>
Interest payments received	10	45
Purchases of investments	-17,194	-20,432
Sales of investments	11,353	41,929
Payments received from escrow amounts and milestones	1,223	0
<b>Net cash flow from investing activities</b>	<b>-4,608</b>	<b>21,542</b>
Interest paid on financial liabilities	-1,787	-4,413
Redemption of financial liabilities	-77,661	-13,219
Purchase of own shares	-9,960	-962
Sale of own shares	1,703	956
<b>Net cash flow from financing activities</b>	<b>-87,705</b>	<b>-17,638</b>
<b>Currency translation differences</b>	<b>249</b>	<b>-133</b>
<b>Net change in cash and cash equivalents</b>	<b>-96,981</b>	<b>-1,895</b>
Cash and cash equivalents at beginning of period	129,084	65,609
Cash and cash equivalents at end of period	32,103	63,714

# Consolidated Quarterly Financial Statements

7

## Consolidated statement of changes in equity

(CHF 000)	Share capital	Treasury shares	Capital reserve	Currency translation differences	Accumulated income/loss	Total shareholders' equity
<b>Balance as at 31.3.2009</b>	<b>675,772</b>	<b>-41,256</b>	<b>359,744</b>	<b>-57</b>	<b>-375,274</b>	<b>618,929</b>
Net result for the period					-4,751	-4,751
<b>Total comprehensive result for the period</b>						<b>-4,751</b>
Purchase of own shares		-962				-962
Sale of own shares		2,586	-1,630			956
<b>Balance as at 30.6.2009</b>	<b>675,772</b>	<b>-39,632</b>	<b>358,114</b>	<b>-57</b>	<b>-380,025</b>	<b>614,172</b>
Net result for the period					70,784	70,784
Currency translation differences				-96		-96
<b>Total comprehensive result for the period</b>						<b>70,688</b>
Purchase of own shares		-28,996				-28,996
Sale of own shares		14,118	-3,834			10,284
Capital reduction (18.11.2009)	-33,772	24,152	9,620			0
<b>Balance as at 31.3.2010</b>	<b>642,000</b>	<b>-30,358</b>	<b>363,900</b>	<b>-153</b>	<b>-309,241</b>	<b>666,148</b>
Net result for the period					-11,626	-11,626
Currency translation differences				-132		-132
<b>Total comprehensive result for the period</b>						<b>-11,758</b>
Purchase of own shares		-9,960				-9,960
Sale of own shares		2,178	-475			1,703
<b>Balance as at 30.6.2010</b>	<b>642,000</b>	<b>-38,140</b>	<b>363,425</b>	<b>-285</b>	<b>-320,867</b>	<b>646,133</b>

# Consolidated Quarterly Financial Statements

## Notes

### 1. Summary of significant accounting policies

The consolidated quarterly financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) IAS 34 on Interim Financial Reporting and the provisions of the SIX Swiss Exchange Additional Rules on the Listing of Investment Companies. These quarterly financial statements should be read in conjunction with the consolidated financial statements for the financial year ended 31 March 2010, as they provide an update to the latest full financial report. In preparing the quarterly financial statements, the same accounting principles and methods of computation have been applied as in the preparation of the annual financial statements.

The use of the new and revised IFRS/IAS standards and interpretations effective as of 1 January 2010 had no impact on the financial condition or the earnings situation of the Company, or on its accounting principles.

### 3. Investments

Investments developed as follows during the reporting period:

(CHF 000)	Private companies	Specialised venture capital funds	Public companies	Total investments
<b>Fair value as at 31 March 2010</b>	<b>440,104</b>	<b>92,500</b>	<b>100,314</b>	<b>632,918</b>
Purchases	13,229	1,562	2,403	17,194
Sales	0	-1,392	-9,961	-11,353
Realised gains	0	312	1,260	1,572
Realised losses	0	0	-2,854	-2,854
Unrealised gains	5,553	9,181	4,196	18,930
Unrealised losses	-20,431	-282	-14,390	-35,103
<b>Fair value as at 30 June 2010</b>	<b>438,455</b>	<b>101,881</b>	<b>80,968</b>	<b>621,304</b>

Details can be found on pages 11 and 12.

The following conversion rates were used in the preparation of the financial statements:

(CHF)	30.6.2010	31.3.2010
DKK	0.1770	0.1912
EUR	1.3185	1.4238
GBP	1.6102	1.6002
SEK	0.1382	0.1460
USD	1.0774	1.0539

### 2. Financial instruments

A significant share of HBM BioVentures' assets is held in US dollars. In May 2010, HBM BioVentures hedged approximately 40% of this USD currency risk by selling forward USD 150 million for November 2010 at a rate of 1.1419. At the balance sheet date, 30 June 2010, the market value and profit contribution of this currency hedging transaction amounted to CHF 10.2 million.

The hedging transaction was closed on 2 July 2010 at a cash profit of CHF 11.5 million.

#### 4. Financial liabilities

The Going Public Convertible Bond was redeemed in full on 19 April 2010.

The following financial liabilities were outstanding within the HBM BioVentures Group as of the balance sheet date:

- > Debtor: HBM BioVentures Ltd  
Nominal CHF 30 million in straight bonds with a coupon of 10%, maturity 16 December 2011, redemption at 100% of par value.
- > Debtor: Tensys Medical Inc.  
USD 6.6 million secured loan, including cumulated interest, interest rate 10%, due 18 September 2010.

#### 5. Treasury shares

The Ordinary Shareholders' Meeting of 4 September 2009 authorised the Board of Directors to repurchase a maximum of 2,140,000 of the Company's own shares via a second trading line in a share buy-back programme. The programme is intended to reduce capital and will run until 31 August 2012 ("2009 share buyback programme").

As at the balance sheet date of 30 June 2010, the Company held 553,511 of its own shares (31 March 2010: 388,951 own shares), acquired as part of this share buy-back programme via a second trading line. In the 3-month period of the current financial year, a total of 164,560 of the Company's own shares were purchased via a second trading line at an average price of CHF 47.13.

At the Ordinary Shareholders' Meeting of 25 June 2010, it was decided that the Company's share capital should be reduced by cancelling 500,000 own shares. The Company's share capital will then amount to CHF 612 million, divided into 10,200,000 shares at a par value of CHF 60 each. Taking into account the statutory periods, the formal execution of the capital reduction will take place in the course of the third quarter 2010.

Additionally, as at the balance sheet date of 30 June 2010, the HBM BioVentures (Cayman) Ltd. subsidiary holds 206,684 treasury shares (31 March 2010: 195,450 treasury shares), which have been purchased over the regular trading line. In the 3-month period until end of June 2010, a total of 47,050 treasury shares were purchased at an average price of CHF 46.86 per share (previous year: 36,065 treasury shares at CHF 26.86) and 35,816 treasury shares were sold at an average price of CHF 47.54 per share (previous year: 36,065 treasury shares at CHF 26.51) via the regular trading line. The loss of CHF 0.5 million (previous year: loss of CHF 1.6 million) from trading in treasury shares, which is reported in shareholders' equity, is based on the proceeds of shares sold minus the pro-rata average acquisition price of all shares purchased over the regular trading line.

#### 6. Investment commitments

(CHF 000)	30.6.2010	31.3.2010
HBM BioCapital (EUR) L.P.	5,465	7,349
Private companies	7,154	15,259
Specialised venture capital funds	24,593	25,843
<b>Total investment commitments</b>	<b>37,212</b>	<b>48,451</b>

#### 7. Management fees

Management fees to HBM Partners for the current financial year amount to 1.5% of gross assets, but are capped at CHF 10 million. In the 3-month period until end of June 2010, HBM Partners was paid CHF 2.9 million (previous year: CHF 3.0 million).

### 8. Transactions with related parties

The remuneration of the Board of Directors and the Management remains unchanged compared with the previous year, with the exception of the emoluments to the Chairman of the Board. These were increased from the previous amount of CHF 70,000 to CHF 120,000 per year for the newly elected Chairman of the Board of Directors. In the 3-month period to 30 June 2010, an accrual amounting to CHF 85,000 was made for emoluments to the five members of the Board of Directors and the Audit Committee (previous year: CHF 90,000 for seven members). The remuneration to the two members of Management for the same period was CHF 67,000 (previous year: CHF 67,000).

HBM BioVentures holds an investment in the Hatteras Venture Partners III specialised venture capital fund, where Robert A. Ingram, Member of the Board of Directors, serves as General Partner. For details on the investment commitment, paid-in capital and valuation, please refer to the overview of specialised venture capital funds on page 12.

## Private companies

	Domicile	Investment currency (IC)	Amount disbursed as at 31.3.2010 (IC m)	Changes in the reporting period (IC m)	Amount disbursed as at 30.6.2010 (IC m)	Fair value as at 30.6.2010 (IC m)	Ownership as % of portfolio company	Fair value as at 30.6.2010 (CHF 000)	Fair value as at 31.3.2010 (CHF 000)
PharmaSwiss	Switzerland	EUR	54.6		54.6	74.2	29.1%	97,789	105,599
PTC Therapeutics	USA	USD	20.5	3.2	23.7	38.7	9.8%	41,674	37,395
mtrm laboratories <sup>1)</sup>	Germany	EUR	21.7		21.7	25.5	33.5%	33,666	36,355
Cathay Industrial Biotech	China	USD	28.0		28.0	28.0	12.4%	30,167	29,509
Pacira Pharmaceutical	USA	USD	26.9	3.8	30.6	20.6	20.1%	22,221	17,785
Lux Biosciences <sup>1)</sup>	USA	USD	16.1	1.0	17.1	17.1	15.6%	18,452	16,962
ChemoCentryx	USA	USD	12.1		12.1	16.9	7.3%	18,232	17,835
Interventional Spine	USA	USD	13.5		13.5	16.0	22.4%	17,224	16,848
Ophthotech	USA	USD	15.4		15.4	15.4	16.9%	16,609	16,247
Nereus Pharmaceuticals <sup>1)</sup>	USA	USD	13.1	0.5	13.6	13.6	9.0%	14,686	13,788
Nabriva Therapeutics <sup>1)</sup>	Austria	EUR	8.9	1.4	10.3	10.3	13.3%	13,553	12,617
Cylene Pharmaceuticals	USA	USD	10.0	1.1	11.1	11.1	11.0%	11,959	10,539
Mpex Pharmaceuticals <sup>1)</sup>	USA	USD	12.0		12.0	8.9	11.8%	9,609	9,399
Medimpulse Holding	Switzerland	USD	4.4		4.4	8.3	20.7%	8,936	8,741
Enanta Pharmaceuticals	USA	USD	7.7		7.7	7.7	6.0%	8,294	8,113
Broncus Technologies <sup>1)</sup>	USA	USD	19.4		19.4	6.6	12.2%	7,069	6,915
Probiodrug	Germany	EUR	13.1		13.1	5.1	12.0%	6,711	7,247
Paratek Pharmaceuticals	USA	USD	5.7		5.7	5.0	3.1%	5,417	5,299
Recorders and Medicare Syst.	India	USD	15.8		15.8	4.9	7.2%	5,267	5,152
Vivacta	UK	GBP	3.1		3.1	3.1	16.6%	4,992	4,961
Devax	USA	USD	21.8	0.5	22.3	4.3	26.3%	4,655	3,991
Cardiac Assist	USA	USD	4.2		4.2	4.2	9.1%	4,504	4,406
Sloning BioTechnology	Germany	EUR	6.7	0.1	6.8	3.1	41.2%	4,136	4,335
Surface Logix	USA	USD	15.6		15.6	3.4	10.2%	3,699	10,072
MiCardia <sup>1)</sup>	USA	USD	3.2		3.2	3.2	8.0%	3,475	3,399
Delenix Therapeutics <sup>1)</sup>	Switzerland	CHF	2.9	0.2	3.1	3.1	13.6%	3,105	2,940
Westmed Holding	USA	USD	5.5		5.5	2.7	12.4%	2,949	2,885
Symphony Evolution	USA	USD	10.0		10.0	2.5	12.5%	2,694	2,635
Other investments								16,711	18,137
<b>Total private companies</b>								<b>438,455</b>	<b>440,104</b>

<sup>1)</sup> As explained in Note 3 of the annual financial statements, this investment was made partly or wholly through HBM BioCapital (EUR) L.P. HBM BioCapital's pro rata fees are reimbursed in full to HBM BioVentures so that fees are not levied twice.

### Specialised venture capital funds

	Domicile	Investment currency (IC)	Total commitment (IC m)	Payments in the reporting period (IC m)	Distributions in the reporting period (IC m)	Cumulative payments as at 30.6.2010 (IC m)	Cumulative distributions as at 30.6.2010 (IC m)	Fair value as at 30.6.2010 (IC m)	Fair value as at 30.6.2010 (CHF 000)	Fair value as at 31.3.2010 (CHF 000)
BioVeda China	China	USD	8.5			8.5	0.9	21.1	22,689	15,599
BioMedInvest I	CH	CHF	26.0			26.0	5.2	21.9	21,882	21,711
Water Street Healthcare	USA	USD	15.0		1.0	12.6	1.3	13.8	14,826	15,223
MedFocus Fund II	USA	USD	16.0			16.0	0.0	12.6	13,618	13,321
Symphony Capital Partners	USA	USD	15.0	0.1		14.6	6.5	7.1	7,695	7,419
Hatteras Venture Partners III	USA	USD	10.0	0.9		4.3	0.0	3.6	3,912	2,905
Galen Partners V	USA	USD	10.0			4.0	0.0	3.5	3,796	3,686
Nordic Biotech	DK	DKK	31.0	1.0		26.8	9.8	16.9	2,992	3,010
BioMedInvest II	CH	CHF	10.0			2.0	0.0	2.7	2,712	2,065
EMBL Technology Fund	GER	EUR	2.1			2.1	0.0	1.7	2,264	2,247
BioVentures Investors II	USA	USD	3.0			3.0	0.5	1.5	1,657	1,633
Heidelberg Innovation BSV II	GER	EUR	5.0	0.2		5.0	0.9	1.2	1,583	1,447
Skyline Venture Partners III	USA	USD	3.0			2.9	2.2	1.4	1,474	1,193
A.M. Pappas LSV II	USA	USD	3.0		0.3	3.0	1.9	0.7	782	1,041
<b>Total specialised venture capital funds</b>									<b>101,881</b>	<b>92,500</b>

### Public companies


	Domicile	Investment currency	Number of shares as at 31.3.2010	Changes in number of shares in the reporting period	Number of shares as at 30.6.2010	Ownership as % of portfolio company	Fair value as at 30.6.2010 (CHF 000)	Fair value as at 31.3.2010 (CHF 000)
Micrus Endovascular <sup>p)</sup>	USA	USD	1,614,203	-126,900	1,487,303	9.0%	33,314	33,548
Basilea Pharmaceutica <sup>p)</sup>	CH	CHF	483,429		483,429	5.0%	29,102	39,520
Swedish Orphan Biovitrum <sup>p)</sup>	Sweden	SEK	1,920,000	-791,000	1,129,000	0.5%	5,790	10,708
SkyePharma	UK	GBP	4,976,806		4,976,806	20.8%	2,164	3,663
China Nuokang Biopharma <sup>p)</sup>	China	USD	355,652		355,652	1.8%	1,832	2,324
Other investments							8,766	10,550
<b>Total public companies</b>							<b>80,968</b>	<b>100,314</b>
<b>Total investments</b>							<b>621,304</b>	<b>632,918</b>

<sup>p)</sup> The position originates from the private companies portfolio.



## Net asset value (NAV) and shares of HBM BioVentures Ltd versus market

in Swiss francs, indexed (12.7.2001 = 100)



### Information on HBM BioVentures Ltd shares

Swiss security number	1.262.725
German security number	984345
ISIN	CH 0012627250
CUSIP	H 3553X112
Telekurs	126,126272
SIX Swiss Exchange Ticker	HBMN
Internet	<a href="http://www.hbmbioventures.com">www.hbmbioventures.com</a>

### Fees

Management fee 2010/2011 (max. 1.5% of gross assets)	CHF 10 million
High water mark per share for all outstanding shares	NAV of CHF 107.71

### Contact

HBM BioVentures Ltd  
 Dr Joachim Rudolf, CFO  
 Bundesplatz 1, CH-6300 Zug, Switzerland  
 Phone +41 41 768 11 08, Fax +41 41 768 11 09  
[info@hbmbioventures.com](mailto:info@hbmbioventures.com)  
[www.hbmbioventures.com](http://www.hbmbioventures.com)

### Board of Directors

Hans Peter Hasler  
 Chairman  
 Prof. Dr Dr h.c. mult. Heinz Riesenhuber<sup>1)</sup>  
 Vice Chairman  
 Dr Eduard E. Holdener  
 Robert A. Ingram<sup>2)</sup>  
 Dr Rudolf Lanz<sup>1)2)</sup>  
 Honorary Chairman  
 Dr Dr h.c. Henri B. Meier

Secretary to the Board of Directors  
 Dr Benedikt Suter

### Management

Dr Andreas Wicki  
 CEO  
 Dr Joachim Rudolf  
 CFO

<sup>1)</sup> Member of the Audit Committee

<sup>2)</sup> Member of Nomination Committee

**HBM BioVentures Ltd**  
Bundesplatz 1  
CH-6300 Zug/Switzerland  
Phone +41 41 768 11 08  
Fax +41 41 768 11 09  
info@hbmbioventures.com  
www.hbmbioventures.com